Biogen Idec, Inc. (BIIB) Misses Q2 EPS by 1c, Sales Beat; Guides FY11
Get Alerts BIIB Hot Sheet
Price: $201.99 +4.56%
EPS Growth %: +7.9%
Financial Fact:
Other: 98.6M
Today's EPS Names:
NLY, CP, RUSHA, More
EPS Growth %: +7.9%
Financial Fact:
Other: 98.6M
Today's EPS Names:
NLY, CP, RUSHA, More
Join SI Premium – FREE
Biogen Idec, Inc. (NASDAQ: BIIB) reported Q2 EPS of $1.36, $0.01 worse than the analyst estimate of $1.37. Revenue for the quarter came in at $1.21 billion versus the consensus estimate of $1.18 billion.
Sees FY11 adj-EPS above $5.70, which compares to the Street estimate of $5.85.
Sees FY11 adj-EPS above $5.70, which compares to the Street estimate of $5.85.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB) tops earnings expectations but revenue falls short
- Biogen (BIIB) Tops Q1 EPS by 24c; reaffirms guidance
- Impinj (PI) Tops Q1 EPS by 11c, provides guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!